Supplemental Figure 6. Phagocytosis of anti-Qβ-coated CMP-001 alone has a modest impact on monocyte phenotype. Monocytes from healthy donors were treated with CMP-001 plus or minus anti-Qβ or G10 (soluble TLR9 agonist) for 18-20 hours. Impact on IDO (A), PDL1 (B), and CXCL10 (C) expression was determined by flow cytometry. Statistical significance was determined using mixed-effects analysis with multiple comparisons test with alpha = 0.05 (ns = not significant; n = 7-12).